<DOC>
	<DOCNO>NCT01947738</DOCNO>
	<brief_summary>Psoriasis inflammatory autoimmune disease might control cathepsin S inhibitor like VBY-891 .</brief_summary>
	<brief_title>Safety Study VBY-891 Healthy Volunteers After Single Multiple ( 7 Days ) Oral Dosing ( VBY891P1 )</brief_title>
	<detailed_description>Refer Brief Summary</detailed_description>
	<criteria>Male female , 1860 year old Screening body mass index 1832 kg/m2 Good health , clinically significant finding medical history , 12lead ECG , &amp; vital sign ; Clinical lab evaluation ( Chem panel [ fast least 8 hrs ] , CBC , HbA1c &amp; UA reference range test lab ( unless deem clinically significant ) ; Negative test drug abuse Screening &amp; Checkin ( include alcohol ) ; Negative hepatitis , HIV &amp; TB screen ; Females nonpregnant , nonlactating , &amp; either postmenopausal least 1 year , surgically sterile least 90 day prior Checkin , agree use time consent 90 day Study Completion effective form contraception . For female , pregnancy test result must negative Screening &amp; Checkin . Males sterile agree use Checkin 90 day follow discharge effective method contraception . Able comprehend &amp; willing sign Informed Consent Form Females pregnant nursing , childbearing potential unwilling use contraception . History renal hepatic impairment ; stomach intestinal surgery resection , malabsorption syndrome , cholecystectomy , gastrointestinal dysfunction would alter absorption &amp; /or excretion orally administer drug ( appendectomy hernia repair allow ) ; Anemia ( hemoglobin &lt; 11.5 g/dL female ; &lt; 13 g/dL male ) blood donation within 8 week Checkin ; Plasma donation within 4 week Checkin ; History alcoholism drug addiction within 6 month Checkin ; Use drug abuse prescription drug recreational use 6 month prior Checkin ; Use tobaccocontaining nicotinecontaining product 6 month prior Checkin &amp; study ; Participation another drug trial 30 day Checkin ( within 8 week previous investigational drug immunomodulatory effect , cathepsin S inhibition ) ; History clinical manifestation metabolic , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , urological , neurological , psychiatric disorder History hypersensitivity allergy drug compound History presence abnormal ECG Laboratory abnormality deem clinically significant ; Use inability discontinue prescription medications/products 14 day prior Checkin &amp; study ; Use certain overthecounter , nonprescription preparation permit 3 day first dose ; Use alcoholcontaining , grapefruitcontaining , star fruit contain food beverages `` energy drink '' 72 hour Checkin &amp; study ; Poor peripheral venous access ; Receipt blood product 6 month Checkin Subjects history Gilbert 's Syndrome ; Strenuous activity 48 hour Checkin Illness 5 day drug administration Any acute chronic condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Subjects</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>VBY891</keyword>
	<keyword>Maximum</keyword>
	<keyword>Pharmacodynamic</keyword>
	<keyword>Pharmacokinetic</keyword>
</DOC>